Dr David Dodwell
BSc, MD, FRCP, FRCR
Senior Clinical Research Fellow
I am a senior breast oncologist based in Leeds with a number of research and governance activities. I am the lead oncologist on the Sloane, NHS screening & national HQIP breast cancer audits.
I am a senior clinical research fellow to the EBCTCG and a member of steering groups for 12 ongoing UK trials in breast cancer. I sit on the trial management committees for 3 trials.
I am UK lead for the SACT project (UK chemotherapy database) and chair the clinical group, which provides input and advice to this project to examine the safety, efficacy and cost-effectiveness of chemotherapy used in England.
Evidence into practice: a national cohort study of NICE-recommended oncological drug therapy utilisation among women diagnosed with invasive breast cancer in England.
Gannon MR. et al, (2023), Br J Cancer
Predicting 10-year breast cancer mortality risk in the general female population in England: a model development and validation study.
Clift AK. et al, (2023), Lancet Digit Health, 5, e571 - e581
Completeness of endocrine therapy information in the Primary Care Prescription Database (PCPD) and secondary care treatment datasets: A national population-based cohort study using routine healthcare data.
Gannon MR. et al, (2023), Cancer Epidemiol, 86
Patterns of chemotherapy use and outcomes in advanced non-small cell lung cancer by age in England: A retrospective analysis of the population-based Systemic Anti-Cancer Treatment (SACT) dataset.
Pilleron S. et al, (2023), J Geriatr Oncol, 14
Breast cancer mortality in 500 000 women with early invasive breast cancer in England, 1993-2015: population based observational cohort study.
Taylor C. et al, (2023), BMJ, 381